Filing Flows › Nuvation Bio (NUVB) › How it makes money
How Nuvation Bio (NUVB) makes money
Nuvation Bio (NUVB) made $45.0M of revenue in the third quarter 2026 (Q3 2026), +244% from a year earlier. Product Revenue brought in $27.5M (61%); License brought in $17.5M (39%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product Revenue | $27.5M | 61.1% | +19% | +257% |
| License | $17.5M | 38.9% | +106% | +224% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $45.0M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $45.0M | +243% |
| Q2 2026 | $31.7M | +556% |
| Q1 2026 | $83.2M | 27× |
| Q4 2025 | $41.9M | +633% |
| Q3 2025 | $13.1M | 18× |
| Q2 2025 | $4.8M | +237% |
| Q1 2025 | $3.1M | — |
From Nuvation Bio's 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does Nuvation Bio make money?
Nuvation Bio (NUVB) made $45.0M of revenue in the third quarter 2026 (Q3 2026), +244% from a year earlier. Product Revenue brought in $27.5M (61%); License brought in $17.5M (39%).
What is Nuvation Bio's biggest business?
Product Revenue: $27.5M in the third quarter 2026, 61% of revenue, +257% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.